You are visiting a website that is not intended for your region

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information.

Switch to the US site

Select Your Country or Region


Getinge Group Q1 Report 2011

Getinge Group Q1 Report 2011

Reporting period January – March

  • Orders received declined by 6.0% to SEK 5,241 M (5,576), and grew organically by 1.1%
  • Net sales declined by 3.9% to SEK 4,671 M (4,863), and grew organically by 3.2%
  • Profit before tax rose by 3.1% to SEK 568 M (551)
  • Net profit increased by 5.0% to SEK 420 M (400)
  • Earnings per share increased by 4.0% to SEK 1.75 (1.68)

  • Continued favourable earnings outlook for 2011

First quarter 2011

Orders received
The Group’s organic orders received increased by 1.1% during the quarter. During the first quarter of the preceding year, a large order was registered for ventilators to Brazil for approximately SEK 250 M in Medical Systems. Adjusted for this order, the organic orders received amounted to slightly less than 6% for the period.

For Medical Systems, orders received declined organically by 2.0% as a result of the aforementioned order. For Extended Care and Infection Control, the organic orders received improved 1.7% and 7.4%, respectively.

From a geographic perspective, the Group's orders received developed according to plan although the Group's business areas exhibited some variation. Demand in Western Europe was unchanged compared with the year-earlier quarter while growth in North America was strong.  Orders received in the emerging markets remained very favourable, taking the aforementioned Brazil order into account.

Getinge AB
Box 69, SE-305 05 Getinge, Sweden
Tel: +46 (0)10-335 00 00. Fax: +46 (0)35-549 52
Corp. Reg. No: 556408-5032

The information given here is information that Getinge AB is obligated to publish under the Securities Exchange and Clearing Operations Act and/or the Financial Instruments Trading Act.